Business Context and Reporting Period
This Form 8-K Current Report is filed by Insulet Corporation for the reporting period of June 24, 2026. The filing primarily addresses corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed relates to director compensation:
- Director Compensation: An initial grant of restricted stock units with a grant date fair value of $216,548 (representing a pro-rated portion of a $260,000 annual award).
Material Changes
The material change reported is the appointment of Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky will stand for election at the 2027 Annual Meeting of Stockholders. His background includes serving as Executive Chair of IDEXX Laboratories, Inc. (since May 2026) and previously as President and CEO of IDEXX.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. It is a disclosure of a corporate event under Item 5.02 and a Regulation FD disclosure under Item 7.01 regarding a press release issued on June 25, 2026.
Investor Verification Checklist
- Verify the effective date of Jonathan J. Mazelsky's directorship (July 1, 2026).
- Confirm the total annualized value of the director compensation package ($260,000).
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Note that this filing does not impact the company's financial statements or operational results.